Company Updates

12th September 2016, ASX Announcement FY16 Achievements Delivered September 2015  Submission of CE Mark application for OncoSil™ October 2015 OncoSil™ CE Mark application granted Fast Track review status December 2015 Investigational Device Exemption (IDE) submitted to the U.S. FDA for OncoPac-1 clinical study January 2016 Chris Roberts appointed Independent Non-Executive Director February 2016 $10 million private […]

12th September 2016, ASX Announcement Rights Issue Crowd Mobile Limited (Crowd Mobile or the Company) is pleased to announce that it is undertaking a pro-rata partially underwritten non-renounceable rights issue (Offer or Rights Issue) Key highlights of the Rights Issue: Rights Issue on a 1:18 basis at an issue price of $0.16 per share to […]

Innovative med-tech company 4Dx is a step closer to commercialising its four-dimensional lung imaging technology after successfully closing a $500,000 retail raise fully subscribed. This comes in addition to the company already raising AU$4m in capital from private investors which will be used to advance the business beyond initial FDA clearance early next year. 4Dx’s […]

August 2016 Over the 12 month period ended 31 August 2016, the Fund returned +29.71% (after fees, before tax), outperforming the Benchmark return of +25.95% by +3.76%. The Monthly Report provides a snapshot of the Fund and the A-REIT sector’s performance. Read more A-REIT REPORTING SEASON What Did We Learn From The A-REIT Reporting Season? […]

9th September 2016, ASX Announcement YPB to provide Brand Protection to Combiphar using the YPB CONNECT platform – expected to be implemented initially across tens of millions of products annually Expected revenue of approx. A$1m over the term of the three-year agreement Combiphar is a leading supplier of prescription and over-the-counter pharmaceuticals with around 170 […]

INVESTMENT OBJECTIVE: To outperform the S&P/ASX All Ordinaries Accumulation Index over rolling three year periods, through active investment in ASX listed securities outside the S&P/ASX 20. INVESTMENT APPROACH: The Fund takes an evidence-based quantitative approach to investing and uses a robust and back-tested trend-following strategy to identify investment opportunities expected to provide both positive price […]

The year’s activities culminated in the signing in July 2016 of a global partnership agreement with Claeris LLC of Dallas, a successful renewables project developer, to build up to five biorefineries.

Alcidion Group Limited (ASX:ALC) today announced that it will hold an investor webinar on Wednesday, 14 September 2016 to present the product portfolio to investors.

As iCompLii powers on, improving, reinventing and strengthening, its a great time to have an update!